Atlantic Edge Private Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$356K Buy
2,270
+40
+2% +$6K 0.07% 114
2026
Q1
$341K Hold
2,230
0.08% 111
2025
Q4
$307K Buy
2,230
+75
+3% +$9.82K 0.08% 113
2025
Q3
$276K Hold
2,155
0.07% 120
2025
Q2
$261K Sell
2,155
-400
-16% -$45.1K 0.07% 118
2025
Q1
$285K Hold
2,555
0.09% 112
2024
Q4
$249K Hold
2,555
0.08% 120
2024
Q3
$294K Buy
2,555
+75
+3% +$8.51K 0.09% 113
2024
Q2
$264K Buy
2,480
+60
+2% +$6.02K 0.09% 110
2024
Q1
$234K Hold
2,420
0.08% 119
2023
Q4
$244K Buy
+2,420
New +$234K 0.1% 112

Other funds holding NVS

Atlantic Edge Private Wealth Management's NVS Position: Q2 2026 in Review

Atlantic Edge Private Wealth Management increased its Novartis (NVS) stake by 1.8% in Q2 2026, buying an estimated $6K and bringing the position to 2,270 shares worth $356K. The position accounts for 0.07% of the portfolio, ranked #114.

Atlantic Edge Private Wealth Management first reported a position in NVS in Q4 2023 and has held it in 11 quarters since. 612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Atlantic Edge Private Wealth Management held 2,270 shares of Novartis worth $356K as of Q2 2026.
  • Atlantic Edge Private Wealth Management bought 40 Novartis shares in Q2 2026, an estimated $6K.
  • Novartis made up 0.07% of Atlantic Edge Private Wealth Management's portfolio in Q2 2026, its #114 holding.
  • Atlantic Edge Private Wealth Management first reported a position in Novartis in Q4 2023 and has held it in 11 quarters since.
  • 612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.